ST-1891
/ Sention Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 26, 2024
A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
(clinicaltrials.gov)
- P2 | N=490 | Completed | Sponsor: Sention Therapeutics, LLC | Active, not recruiting ➔ Completed
Trial completion • Endocrine Disorders
May 09, 2023
A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
(clinicaltrials.gov)
- P2 | N=490 | Active, not recruiting | Sponsor: Sention Therapeutics, LLC | Trial primary completion date: Jun 2023 ➔ Dec 2023
Trial primary completion date • Endocrine Disorders
November 10, 2022
A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
(clinicaltrials.gov)
- P2 | N=490 | Active, not recruiting | Sponsor: Sention Therapeutics, LLC | Recruiting ➔ Active, not recruiting | N=300 ➔ 490
Enrollment change • Enrollment closed • Endocrine Disorders
June 09, 2022
A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
(clinicaltrials.gov)
- P2 | N=300 | Recruiting | Sponsor: Sention Therapeutics, LLC
New P2 trial • Endocrine Disorders
1 to 4
Of
4
Go to page
1